The clinical value of Tc-99m TRODAT-1 SPECT for evaluating disease severity in young patients with symptomatic and asymptomatic Wilson disease

Clinical Nuclear Medicine

Volumn 32, Issue 11, 2007, Pages 844-849

  Wang, Ping ^a   Hu, Ping ^a   Yue, Dian Chao ^a   Liang, Hong ^a   Xu, Jie Hua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Dopamine transporter; Hepatolenticular degeneration; SPECT; Tc 99m TRODAT 1

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE TRANSPORTER;

ADOLESCENT; ADULT; ARTICLE; BRAIN REGION; CEREBELLUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DRUG UPTAKE; FEMALE; HUMAN; MALE; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; PRESYNAPTIC NERVE; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WILSON DISEASE;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; CORPUS STRIATUM; FEMALE; HEPATOLENTICULAR DEGENERATION; HUMANS; MALE; ORGANOTECHNETIUM COMPOUNDS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 37349020045     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318156baf8     Document Type: Article

References (43)

1. Sternlieb I. Perspectives on Wilson's disease [Review]. Hepatology. 1990;12:1234-1239.
2. Bull PC, Thomas GR, Rommens JM, et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993;5:327-337.
3. Gollan JL, Gollan TJ. Wilson disease in 1998: genetic, diagnostic and therapeutic aspects [Review]. J Hepatol. 1998;28(Suppl 1):28-36.
4. Yuce A, Kocak N, Gurakan F, et al. Wilson's disease with hepatic presentation in childhood. Indian Pediatr. 2000;37:31-36.
5. Oder W, Grimm G, Kollegger H, et al. Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases. J Neurol. 1991;238:281-287.
6. Liu M, Cohen EJ, Brewer GJ, et al. Kayser-Fleischer ring as the presenting sign of Wilson disease. Am J Ophthalmol. 2002;133:832-834.
7. Gow PJ, Smallwood RA, Angus PW, et al. Diagnosis of Wilson's disease: an experience over three decades. Gut. 2000;46:415-419.
8. van Wassenaer-van Hall HN, van den Heuvel AG, Algra A, et al. Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology. 1996;198:531-536.
9. Kim TJ, Kim IO, Kim WS, et al. MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation. AJNR Am J Neuroradiol. 2006;27:1373-1378.
10. Saatci I, Topcu M, Baltaoglu FF, et al. Cranial MR findings in Wilson's disease. Acta Radiol. 1997;38:250-258.
11. Barthel H, Hermann W, Kluge R, et al. Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease. AJNR Am J Neuroradiol. 2003;24:234-238.
12. Snow BJ, Bhatt M, Martin WR, et al. The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography. J Neurol Neurosurg Psychiatry. 1991;54:12-17.
13. Oder W, Brucke T, Kollegger H, et al. Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding. J Neural Transm. 1996;103:1093-1103.
14. Oertel WH, Tatsch K, Schwarz J, et al. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease. Ann Neurol. 1992;32:743-748.
15. Kung HF. Development of Tc-99m labeled tropanes: TRODAT-1, as a dopamine transporter imaging agent. Nucl Med Biol. 2001;28:505-508.
16. Lu CS, Weng YH, Chen MC, et al. 99mTc-TRODAT-1 imaging of multiple system atrophy. J Nucl Med. 2004;45:49-55.
17. Tzen KY, Lu CS, Yen TC, et al. Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J Nucl Med. 2001;42:408-413.
18. la Fougere C, Krause J, Krause KH, et al. Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. Nucl Med Commun. 2006;27:733-737.
19. Huang CC, Yen TC, Weng YH, et al. Normal dopamine transporter binding in dopa responsive dystonia. J Neurol. 2002;249:1016-1020.
20. Swanson RL, Newberg AB, Acton PD, et al. Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease. Eur J Nucl Med Mol Imaging. 2005;32:302-307.
21. Young AB, Shoulson I, Penney JB, et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology. 1986;36:244-249.
22. Fang P, Wu CY, Liu ZG, et al. The preclinical pharmacologic study of dopamine transporter imaging agent [99mTc]TRODAT-1. Nucl Med Biol. 2000;27:69-75.
23. Hu P, Chen L, Zhang HQ, et al. Single photon emission computer tomography of dopamine transporters in monkeys and humans with 99mTc-TRODAT-1. Chin Med J (Engl). 2004;117:1056-1059.
24. Eshuis SA, Maguire RP, Leenders KL, et al. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease. Eur J Nucl Med Mol Imaging. 2006;33:200-209.
25. Davis MR, Votaw JR, Bremner JD, et al. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med. 2003;44:855-861.
26. Lorberboym M, Djaldetti R, Melamed E, et al. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med. 2004;45:1688-1693.
27. Jucaite A, Odano I, Olsson H, et al. Quantitative analyses of regional [(11)C]PE2I binding to the dopamine transporter in the human brain: a PET study. Eur J Nucl Med Mol Imaging. 2006;33:657-668.
28. Asenbaum S, Pirker W, Angelberger P, et al. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm. 1998;105:1213-1228.
29. Jeon B, Kim JM, Jeong JM, et al. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psychiatry. 1998;65:60-64.
30. Barthel H, Sorger D, Kuhn HJ, et al. Differential alteration of the nigrostriatal dopaminergic system in Wilson's disease investigated with [123I]ss-CIT and high-resolution SPET. Eur J Nucl Med. 2001;28:1656-1663.
31. Kuikka JT, Tiihonen J, Bergstrom KA, et al. Imaging of serotonin and dopamine transporters in the living human brain. Eur J Nucl Med. 1995;22:346-350.
32. Pirker W, Asenbaum S, Hauk M, et al. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med. 2000;41:36-44.
33. Laruelle M, Abi-Dargham A, van Dyck C, et al. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry. 2000;47:371-379.
34. Haapaniemi TH, Ahonen A, Torniainen P, et al. [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord. 2001;16:124-130.
35. Kozic D, Svetel M, Petrovic B, et al. MR imaging of the brain in patients with hepatic form of Wilson's disease. Eur J Neurol. 2003;10:587-592.
36. Kendall BE, Pollock SS, Bass NM, et al. Wilson's disease. Clinical correction with cranial computed tomography. Neuroradiology. 1981;22:1-5.
37. King AD, Walshe JM, Kendall BE, et al. Cranial MR imaging in Wilson's disease. AJR Am J Roentgenol. 1996;167:1579-1584.
38. Ferenci P. Pathophysiology and clinical features of Wilson disease [Review]. Metab Brain Dis. 2004;19:229-239.
39. Volkow ND, Ding YS, Fowler JS, et al. Dopamine transporters decrease with age. J Nucl Med. 1996;37:554-559.
40. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry. 2002;10:36-43.
41. Mozley PD, Acton PD, Barraclough ED, et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med. 1999;40:1812-1817.
42. Kuikka JT, Tupala E, Bergstrom KA, et al. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects. Eur J Nucl Med. 1999;26:1486-1488.
43. Lavalaye J, Booij J, Reneman L, et al. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27:867-869.